Industry
Drug Manufacturers - Specialty & Generic
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Loading...
Open
11.76
Mkt cap
1.1B
Volume
1.6M
High
12.22
P/E Ratio
-15.55
52-wk high
19.09
Low
11.53
Div yield
N/A
52-wk low
10.41
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.